SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Burke William Patrick
(Last) (First) (Middle)
20 VALLEY STREAM PARKWAY
SUITE 300
(Street)
MALVERN PA 19355
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
09/01/2021 		3. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Human Resources Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares 10,283 D
Restricted Share Units 2,657(1) D
Restricted Share Units 4,804(2) D
Restricted Share Units 1,573(3) D
Restricted Share Units 3,266(4) D
Restricted Share Units 3,634(5) D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Options to Buy Ordinary Shares (6) 02/24/2026 Ordinary Shares 17,452 $11.46 D
Options to Buy Ordinary Shares (6) 02/21/2027 Ordinary Shares 9,750 $7.15 D
Options to Buy Ordinary Shares (7) 10/30/2027 Ordinary Shares 7,500 $21.6 D
Options to Buy Ordinary Shares (8) 02/26/2028 Ordinary Shares 32,103 $21.15 D
Options to Buy Ordinary Shares (9) 03/21/2029 Ordinary Shares 10,946 $47.04 D
Options to Buy Ordinary Shares (10) 03/02/2030 Ordinary Shares 13,896 $69.37 D
Options to Buy Ordinary Shares (11) 08/31/2030 Ordinary Shares 4,535 $84.68 D
Options to Buy Ordinary Shares (12) 03/01/2031 Ordinary Shares 6,001 $153.09 D
Options to Buy Ordinary Shares (13) 08/31/2031 Ordinary Shares 6,531 $137.58 D
Explanation of Responses:
1. Represents restricted share units that are scheduled to vest on March 22, 2022, subject to the reporting person's continued employment through such date.
2. Represents restricted share units that are scheduled to vest on March 3, 2022 and 2023, subject to the reporting person's continued employment through such dates.
3. Represents restricted share units that are scheduled to vest on September 1, 2022 and 2023, subject to the reporting person's continued employment through such dates.
4. Represents restricted share units that are scheduled to vest on March 2, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates.
5. Represents restricted share units that are scheduled to vest on September 1, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates.
6. Fully vested as of the date hereof.
7. These options vest on October 31, 2021, subject to the reporting person's continued employment through such date.
8. Options to buy 32,103 ordinary shares, 24,078 shares of which are currently exercisable and the remaining 8,025 vest and become exercisable on February 27, 2022, subject to the reporting person's continued employment through such date.
9. Options to buy 10,946 ordinary shares, 3,649 shares of which are currently exercisable and the remaining 7,297 shares of which will vest and become exercisable in equal installments on each of March 22, 2022 March 22, 2023, subject to the reporting person's continued employment through such dates.
10. Options to buy 13,896 ordinary shares, 3,474 shares of which are currently exercisable and the remaining 10,422 shares will vest and become exercisable in equal installments on each of March 3, 2022, March 3, 2023 and March 3, 2024, subject to the reporting person's continued employment through such dates.
11. Options to buy 4,535 ordinary shares, 1,134 shares of which are currently exercisable and the remaining 3,401 shares will vest and become exercisable in equal installments on each of September 1, 2022, September 1, 2023 and September 1, 2024, subject to the reporting person's continued employment through such dates.
12. One-quarter of these options is scheduled to vest on each of March 2, 2022, March 2, 2023, March 2, 2024 and March 2, 2025, subject to the reporting person's continued employment through such dates.
13. One-quarter of these options is scheduled to vest on each of September 1, 2022, September 1, 2023, September 1, 2024 and September 1, 2025, subject to the reporting person's continued employment through such dates.
Remarks:
By: /s/ Steven Robbins, Attorney in Fact for William Patrick Burke 09/03/2021
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.